Medical Devices India

India Automated Insulin Delivery Systems Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

India Automated Insulin Delivery Systems Market Industry Trends and Forecast to 2034: Segmented by (Component, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

India · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $55.2 Mn Placeholder estimate
Estimate 2025 $66.4 Mn 1.9% of the global market
Projected 2034 $344.9 Mn 419.9% Adds $278.6 Mn over 9 forecast years
CAGR 2025–2034 20.1% Faster than 91% of 173 Medical Devices markets here
Key players 6 +1
  • India is 1.86% of the global market.
  • In APAC, the largest is China at $266.9 Mn.
  • Fastest growing: India (this report) at 20.1% a year.
  • India ranks 3rd of 10 by size in APAC.

Market size projection

India

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$278.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Automated Insulin Delivery Systems Market market size by year, India
YearMarket sizeChange that yearSince 2025
2024 (estimate) $55.2 Mn — —
2025 (base) $66.4 Mn +$11.1 Mn —
2026 (forecast) $79.7 Mn +$13.3 Mn +20.1%
2027 (forecast) $95.7 Mn +$16.0 Mn +44.2%
2028 (forecast) $114.9 Mn +$19.2 Mn +73.2%
2029 (forecast) $138.0 Mn +$23.1 Mn +108.1%
2030 (forecast) $165.8 Mn +$27.7 Mn +149.9%
2031 (forecast) $199.1 Mn +$33.3 Mn +200.1%
2032 (forecast) $239.1 Mn +$40.0 Mn +260.4%
2033 (forecast) $287.2 Mn +$48.1 Mn +332.9%
2034 (forecast) $344.9 Mn +$57.7 Mn +419.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

India Automated Insulin Delivery Systems Market Analysis at a glance
Market size, 2025$66.4 Mn placeholder estimate
Forecast, 2034$344.9 Mn placeholder estimate
Growth (CAGR), 2025–203420.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsComponent, type and end user (see all)
Key playersMedtronic, Tandem Diabetes Care, Insulet Corporation, Dexcom, Inc., Abbott Laboratories and 1 more (see all)
Regulator in IndiaCDSCOSource: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
Active clinical trials7 in IndiaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The India Automated Insulin Delivery Systems Market Analysis Executive Summary

Automated insulin delivery systems link an insulin pump with a glucose sensor and software that adjusts insulin doses automatically.

Key segments of the automated Insulin Delivery Systems market include component (Insulin Pumps, CGM Sensors and Control Algorithms) and type (Hybrid Closed Loop and Advanced Hybrid Closed Loop).

Bar chart: India Automated Insulin Delivery Systems market size, 2024–2034, placeholder estimates. $55.2 Mn in 2024, $66.4 Mn in 2025 and $344.9 Mn in 2034, 20.1% CAGR.
India Automated Insulin Delivery Systems market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

India Automated Insulin Delivery Systems Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the automated Insulin Delivery Systems market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the automated Insulin Delivery Systems market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the automated Insulin Delivery Systems market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Automated Insulin Delivery Systems Market in India

The automated Insulin Delivery Systems market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Automated Insulin Delivery Systems Market in India

Automated Insulin Delivery Systems in India: rules, payment and research

Since October 2023, every medical device sold in India needs a licence under the Medical Devices Rules, 2017, from the Central Drugs Standard Control Organisation (CDSCO) or, for some lower-risk devices made in India, a state authority.⁠[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.⁠[2] ClinicalTrials.gov lists 7 studies on Automated Insulin Delivery Systems that are recruiting, active or about to start in India.⁠[3] Diabetes (adults): 22.6% of adults in 2022, the latest WHO figure for India.⁠[4]

[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how automated Insulin Delivery Systems products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in India.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Automated Insulin Delivery Systems right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Automated Insulin Delivery Systems in context

India compared

  • Diabetes (adults, WHO): 22.6% of adults (2022). World: 14.1% of adults (2022). 4th highest of the 15 countries we cover in APAC.[1]
  • Health spending per person: 85 US$ per person (2023). World: 1,317 US$ per person (2023). 10th highest of the 15 countries we cover in APAC.[2]
  • Doctors: 0.72 per 1,000 people (2020). World: 1.86 per 1,000 people (2022). 11th highest of the 15 countries we cover in APAC.[3]

[1] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 18 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Automated Insulin Delivery Systems market in India?
Placeholder estimate: about $66.4 Mn in 2025, rising to about $344.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Automated Insulin Delivery Systems market in India growing?
Placeholder estimate: about 20.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Automated Insulin Delivery Systems market report cover?
The report splits the market by component (Insulin Pumps, CGM Sensors, Control Algorithms), type (Hybrid Closed Loop, Advanced Hybrid Closed Loop) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Automated Insulin Delivery Systems market?
Key players include Medtronic, Tandem Diabetes Care, Insulet Corporation, Dexcom, Inc., Abbott Laboratories and Beta Bionics.
What is driving the Automated Insulin Delivery Systems market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the automated Insulin Delivery Systems market.
Who regulates Automated Insulin Delivery Systems in India?
Since October 2023, every medical device sold in India needs a licence under the Medical Devices Rules, 2017, from the Central Drugs Standard Control Organisation (CDSCO) or, for some lower-risk devices made in India, a state authority. Source: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
How is healthcare paid for in India?
Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year. Source: National Health Authority (PM-JAY). Checked 14 Nov 2026.
How many clinical trials on Automated Insulin Delivery Systems are running in India?
7 studies are recruiting, active or about to start in India, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 12 Nov 2026.
What does WHO report for India?
Diabetes (adults): 22.6% of adults in 2022, the latest WHO figure. Source: WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 15 Nov 2026.
How many people in India are 65 or older?
7.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 19 Nov 2026.
Back to Catalogue

Related Medical Devices reports in India

See all

Related on diabetes and remote monitoring and wearables

See the topic